TICKERNERD
Menu
NVSTNVSTHealthcare · Medical Instruments & Supplies

NVST Stock Forecast: Envista Holdings Corp. Price Predictions for 2026-2027

Last close, 5 Oct 2026
$23
−0.51% on the day

The 15 Wall Street analysts covering Envista Holdings Corp. hold a median 12-month price target of $31 — +32.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 98 of 100 as at 3 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$3.8B
Ticker Nerd rank
98 / 100
Median analyst target
$31
Analysts covering
15
Revenue$730.5M+7.1% y/y
Operating income$80.3M
Net income$53.7M
Free cash flow$104.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.6%
1M
−14.4%
YTD
+7.5%
1Y
+11.9%
From 52W high
−22.9%
From 52W low
+23.2%
$19
$30
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NVST stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Envista Holdings Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
98 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
97
Revisions
95
Volatility
85
Issuance
85
Growth
74
Accruals
71
Quality
69
Momentum
68
Size
27

Value (97): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (68): The shares have been drifting down relative to others.

Size (27): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NVST stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NVST, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$25$30$35Jan 26Apr 26Jul 26Oct 26NVSTHigh $35Median $31Low $23

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
8 Buy7 Hold0 Sell
Low $23Median $31High $35

The green dot is the last close — the median target sits +32.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
28 Sept 2026BMO CapitalMaintainsMarket Perform$29 → $26
18 Sept 2026NeedhamReiteratesHold—
18 Sept 2026NeedhamReiteratesHold—
18 Sept 2026Piper SandlerReiteratesNeutral—
18 Sept 2026Piper SandlerReiteratesNeutral$28
18 Sept 2026UBSMaintainsNeutral—
18 Sept 2026UBSMaintainsNeutral$30 → $27
3 Sept 2026JP MorganUpgradeOverweight—
3 Sept 2026JP MorganUpgradeOverweight$29 → $32
6 Aug 2026Piper SandlerReiteratesNeutral$26 → $28
6 Aug 2026Piper SandlerReiteratesNeutral—
29 July 2026Piper SandlerMaintainsNeutral$25 → $26
29 July 2026Piper SandlerMaintainsNeutral—
9 July 2026BMO CapitalInitiatesMarket Perform—
9 July 2026BMO CapitalInitiatesMarket Perform$27
11 June 2026BarclaysMaintainsOverweight—
7 May 2026BairdMaintainsOutperform—
7 May 2026Evercore ISI GroupMaintainsOutperform—
7 May 2026JP MorganMaintainsNeutral—
24 Apr 2026Morgan StanleyMaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NVST appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NVST vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 5 Oct 2026, Envista Holdings Corp. returned +11.9% against +16.2% for the S&P 500, dividends included.

NVST vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150Jan 26Apr 26Jul 26Oct 26NVSTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NVST analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+7.0%
Analysts raising
16
Analysts cutting
0
Fundamentals

Envista Holdings Corp. (NVST) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
40.4×

Cheaper than 18% of US stocks

Price / sales
1.3×

Cheaper than 62% of US stocks

Price / book
1.2×

Cheaper than 65% of US stocks

EV / EBITDA
10.4×

Cheaper than 36% of US stocks

Growth & margins
Revenue growth (YoY)
7.1%

Higher than 44% of US stocks

Earnings growth (YoY)
103.4%

Higher than 84% of US stocks

Gross margin
55.7%

Higher than 69% of US stocks

Operating margin
10.4%

Higher than 65% of US stocks

Net margin
3.3%

Higher than 56% of US stocks

Returns & dividend
Return on equity
3.1%

Higher than 50% of US stocks

Return on assets
3.2%

Higher than 66% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Envista Holdings Corp. (NVST) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Envista Holdings Corp. has a market value of $3.8B and an enterprise value of $4.2B.

  • Revenue in the twelve months to 30 June 2026: $2.9B. The latest quarter grew 7.1% year on year.

  • Net income over the same four quarters: $95.0M, a 3.3% net margin.

  • Diluted earnings per share, trailing twelve months: $0.58.

  • Free cash flow in the twelve months to 30 June 2026: $248.1M.

  • Envista Holdings Corp. spent $169.3M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 160.6M.

  • Trailing P/E: 40.4×; forward P/E: 14.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Envista Holdings Corp. employs 12,000 people — $238K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Oct 2026

Data provided by Twelve Data

Peers

NVST vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
NVSTEnvista Holdings Corp.$3.8B
98
ICUIICU Medical, Inc.$3.9B
97
PLSEPulse Biosciences, Inc.$3.5B
42
WRBYWarby Parker, Inc.$3.3B
30
ATRCAtriCure, Inc.$2.8B
94
MMSIMerit Medical Systems, Inc.$5.1B
92
TFXTeleflex, Inc.$5.5B
80

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Envista Holdings Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NVST news & analysis

New Strong Buy Stocks for September 28th

Zacks Investment Research · 28 Sept 2026positive

On September 28, 2026, Zacks Investment Research added Envista Holdings Corp. (NVST) to its Zacks Rank #1 (Strong Buy) List, alongside VG, HCSG, EQNR, and HMN. The addition places NVST among stocks rated as Strong Buy by Zacks.

Why it matters — This signals that Zacks' quantitative rating system has placed NVST in its top tier of recommended stocks, a development investors tracking the company may view favorably.

NVST vs. ABT: Which Stock Is the Better Value Option?

Zacks Investment Research · 25 Sept 2026neutral

Zacks Investment Research published a value comparison between Envista (NVST) and Abbott (ABT), both in the Medical - Products sector, evaluating which may be the better option for investors seeking undervalued stocks. The article frames the question but the excerpt does not provide a conclusion.

Why it matters — The piece places NVST in a direct valuation context against a major medical-products peer, offering investors a comparative frame for assessing the stock.

Best Value Stocks to Buy for September 21st

Zacks Investment Research · 21 Sept 2026positive

On September 21st, 2026, NVST was added to the Zacks Rank #1 (Strong Buy) value stocks list alongside SLDE and HHH, according to an article from Zacks Investment Research.

Why it matters — NVST being named to a Strong Buy value stocks list indicates favorable analyst ranking that NVST watchers would take note of.

Should Value Investors Buy Envista (NVST) Stock?

Zacks Investment Research · 18 Sept 2026neutral

Zacks Investment Research published an article asking whether value investors should buy Envista (NVST) stock. The piece describes the Zacks Rank system, which emphasizes earnings estimates and estimate revisions, while also tracking value, growth, and momentum trends to help identify strong stock picks.

Why it matters — NVST watchers would care because the article signals that analysts are evaluating Envista within the context of the Zacks Rank and value-based screening frameworks, potentially drawing attention to the stock.

Down 12% in 4 Weeks, Here's Why You Should You Buy the Dip in Envista (NVST)

Zacks Investment Research · 18 Sept 2026positive

Envista (NVST) has dropped 12% over four weeks and is now considered technically oversold. This, along with strong agreement among Wall Street analysts in revising earnings estimates higher, suggests a potential near-term trend reversal for the stock.

Why it matters — NVST watchers would care because analyst earnings-estimate revisions and oversold conditions could signal a shift in the stock's near-term direction.

FAQ

Frequently asked questions about NVST stock

What is the NVST stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Envista Holdings Corp. have a median 12-month price target of $31, with estimates ranging from $23 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NVST stock a buy right now?

Of the 15 analysts covering Envista Holdings Corp., 8 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Envista Holdings Corp. 98 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NVST?

As at 3 Oct 2026, Envista Holdings Corp. ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (97 of 100).

Will NVST stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +32.8% from the last close, and Ticker Nerd's factor model ranks Envista Holdings Corp. 98 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NVST stock forecast for 2030?

No analyst covering Envista Holdings Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NVST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $35 over the next 12 months.

How has NVST stock performed over the past year?

Envista Holdings Corp. returned +11.9% over the 12 months to 5 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Envista Holdings Corp. do?

Envista Holdings Corp. is a global dental products company that develops, manufactures, and markets a broad range of solutions for dental professionals.

What is the latest news on NVST?

The most recent item we track (Zacks Investment Research, 28 Sept 2026): "New Strong Buy Stocks for September 28th". On September 28, 2026, Zacks Investment Research added Envista Holdings Corp. (NVST) to its Zacks Rank #1 (Strong Buy) List, alongside VG, HCSG, EQNR, and HMN. The addition places NVST among stocks rated as Strong Buy by Zacks.

Company

About Envista Holdings Corp.

Envista Holdings Corp. is a global dental products company that develops, manufactures, and markets a broad range of solutions for dental professionals. Its portfolio spans dental implants, orthodontic systems and aligners, imaging and digital workflow tools, restorative and endodontic products, and consumables used in everyday dental practice. The company serves clinical needs across prevention, diagnosis, treatment, and aesthetics, supporting dentists, oral surgeons, prosthodontists, and orthodontists with equipment, software, and branded consumables. Envista operates through two main business segments, Specialty Products & Technologies and Equipment & Consumables, and its products are used across dental offices, laboratories, and surgical settings worldwide. Headquartered in Brea, California, Envista holds a meaningful position in the dental technology and medical products market through a diversified family of dental brands.

CEO Mr. Paul A. Keel · 12,000 employees · United States · https://envistaco.com